Market Place
Sourcing Support
All News #Library
Rare Diseases
Merck Advances Winrevair To Pivotal Study Despite Dose Concerns
30 Mar 2026 //
BIOSPACE
Merck mulls PV program’s future while Takeda takes victory lap
08 Dec 2025 //
FIERCE BIOTECH
EU Grants Conditional Approval of Ezmekly for Patient with NF1-PN
18 Jul 2025 //
GLOBENEWSWIRE
Merck Showcases Innovation in Advanced Cancers and Rare Tumors
22 May 2025 //
BUSINESSWIRE
FDA expands use of Merck`s cancer drug for adrenal gland tumors
15 May 2025 //
REUTERS
FDA Approves Merck’s Welireg for Rare PPGL Tumor Treatment
14 May 2025 //
BUSINESSWIRE
Merck`s therapy for rare lung condition to help reduce risk of death
26 Nov 2024 //
REUTERS
Merck, AstraZeneca Announce Phase 3 Win for Cancer Drug
12 Nov 2024 //
FIERCE BIOTECH
Merck aims to `outnumber` pulmonary arterial hypertension
16 Apr 2024 //
FIERCE PHARMA
India exempts import tax on pricey rare disease medicines
31 Mar 2023 //
REUTERS
FDA fires off a warning on rare cases involving death, adverse liver events
29 Aug 2019 //
ENDPTS
Rare Disease R&D Investments Likely To Grow In Biopharma
24 Apr 2019 //
FORBES
Catalyst will charge $375,000 for rare disease drug
13 Dec 2018 //
STAT NEWS
AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures
26 Jul 2018 //
FIERCE BIOTECH
A US senator calls out little biotech for price gouging - will change anything?
21 Dec 2017 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.